1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Lilly To Deliver More Proof Points In Obesity, Keep Building Pipeline In 2024

Zepbound Readouts Expected In Co-Morbidities

 
• By Mandy Jackson

Research head Dan Skovronsky said it’s hard to improve upon tirzepatide, but Lilly is advancing early and late-stage obesity drugs while investigating internal and external assets in weight loss and beyond.

Lilly San Diego
Lilly will have readouts in obesity-related diseases for Zepbound in 2024 • Source: Shutterstock

Eli Lilly and Company’s obesity pipeline had a standout year in 2023 that will be hard to top in 2024, but the drug maker will continue delivering data to show the impact that significant weight loss with GLP-1/GIP agonist tirzepatide can have on related co-morbidities. And while the company awaits Phase III results from its next-generation obesity medicines retatrutide and orforglipron in 2025, it continues to scour the biopharmaceutical landscape for additional drug candidates.

Key Takeaways

  • Lilly will focus on its Zepbound launch and additional readouts for the obesity drug in 2024 while advancing its next-generation weight loss medicines.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

More from Conferences

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.